Oncopeptalks

In this premiere episode of Oncopeptalks in a brand-new podcast format, we sit down with Sofia Heigis, CEO of Oncopeptides, to discuss the company’s core mission, and what it actually takes to market an advanced cancer treatment in Europe.

We’re going back to basics:

*What is the company’s flagship drug, and which patients is it intended for?
*Why has Oncopeptides launched specifically in Germany, Austria, Spain, and Italy, and not the rest of Europe?
*How long does it really take before a doctor feels ready to prescribe a new treatment to their most critically ill patients?

This episode is for anyone who wants an inside look at Oncopeptides, whether you are a new listener or have followed the company for years. The content is in Swedish only.

In the latest, and “final”, Oncopeptalks, Sofia covers, among other things, congress season, and David provides some updates from the communications side – including that Oncopeptalks will take on a new shape in the future.

In the latest episode of Oncopeptalks, Sofia Heigis talks more about recent initiatives to strengthen access to real‑world data in the company’s key markets. She also answers a number of questions from investors on everything from the sales landscape in Germany and Italy to the recently completed share issue.

The video is available in Swedish, with Swedish or English subtitles.

In the latest episode of Oncopeptalks, David and Sofia talk about the newly released Q4 report, the ongoing rights issue and news about our pipeline. The video is available in Swedish with English subtitles.

In the last episode of the year, David and Sofia discuss the key takeaways from the year and from ASH. The video is available in Swedish with English subtitles.